Correction to: Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan

Affiliations

• ¹ Department of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. s.takahashi-chemotherapy@jfcr.or.jp.
• ² Department of Head and Neck Cancer Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan.
• ³ Ito Hospital, 4-3-6 Jingu-mae, Shibuya-ku, Tokyo, 150-8308, Japan.
• ⁴ Department of Endocrine Surgery, Osaka Police Hospital, 10-31, Kitayamacho, Tennouji-ku, Osaka, 543-0035, Japan.
• ⁵ Oncology/Hematology, Kobe University Hospital Cancer Center, 7-5-1, Kusunokicho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
• ⁶ Eisai Co. Ltd., 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, 112-8088, Japan.
• ⁷ Kanagawa Health Service Association, Nihon-odori bldg. 58 Nihon-odori, Naka-ku, Yokohama, 231-0021, Japan.